Blog
RSS FeedPosted by Michael Wonder on 26 Jun 2025
FDA grants RMAT designation for enGene’s detalimogene, enabling potential for expedited review in high risk, non-muscle invasive bladder cancer
25 June 2025 - enGene Holdings today announced that the US FDA has granted regenerative medicine advanced therapy designation to detalimogene ...
Posted by Michael Wonder on 31 Oct 2019
Where were the women? Gender parity in clinical trials
30 October 2019 - On October 3, the FDA approved co-formulated tenofovir alafenamide and emtricitabine (F/TAF) for HIV prevention in at-risk ...